{"id":"W2996090129","doi":"10.1158/1078-0432.ccr-19-1638","title":"A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"National Cancer Institute; V Foundation for Cancer Research","keywords":"Carboplatin; Gemcitabine; Internal medicine; Medicine; Topotecan; Neutropenia; Ovarian cancer; Clinical endpoint; Oncology; Leukopenia; Phases of clinical research; Chemotherapy; Cancer; Gastroenterology; Clinical trial; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004126654,0.000153377,0.0006028687,0.0001211786,0.00006635284,0.00001961659,0.0001763654,0.0002091986,0.00009670677],"category_scores_gemma":[0.000886015,0.0001199562,0.00009041198,0.0002592882,0.0003602549,0.000004643807,0.0001895875,0.0003692257,9.995932e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003431298,"about_ca_system_score_gemma":0.0004964338,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000712414,"about_ca_topic_score_gemma":0.001212321,"domain_scores_codex":[0.997018,0.0008179429,0.0008175045,0.000561635,0.0004300227,0.0003549256],"domain_scores_gemma":[0.998491,0.0005172946,0.0002128878,0.0003818288,0.0002624977,0.00013442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7637039,0.0006500764,0.00494841,0.0001043831,0.0001492772,0.000003275466,0.0002085821,0.0001481201,0.1816851,0.00008272609,0.00003078037,0.04828545],"study_design_scores_gemma":[0.9141942,0.01034086,0.003992861,0.0002804478,0.00006172389,3.37102e-7,0.0000753444,0.00092129,0.06663801,0.0003627044,0.002827774,0.0003045035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890245,0.008194629,0.00009481294,0.0002796358,0.0002159665,0.001670909,0.00003298516,0.000003227849,0.0004833738],"genre_scores_gemma":[0.9924692,0.00622418,0.0003393281,0.00001741477,0.000289006,0.0002842725,0.00002756015,0.00002540361,0.000323663],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1504903,"threshold_uncertainty_score":0.489167,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.113838503015016,"score_gpt":0.4829287768198101,"score_spread":0.369090273804794,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}